{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T22:48:27Z","timestamp":1750891707872,"version":"3.28.0"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"15","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1055\/a-2328-7240","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:58:03Z","timestamp":1720047483000},"page":"e58-e66","source":"Crossref","is-referenced-by-count":1,"title":["Orale Antikoagulation mit Edoxaban zur Schlaganfallpr\u00e4vention bei Patienten mit Vorhofflimmern: Analyse der Ein-Jahres-Follow-up-Daten aus dem ETNA-AF-Register zur klinischen Routinepraxis in Deutschland, \u00d6sterreich und der Schweiz (DACH)"],"prefix":"10.1055","volume":"149","author":[{"given":"Leon","family":"Dinshaw","sequence":"additional","affiliation":[{"name":"Universit\u00e4res Herz- und Gef\u00e4\u00dfzentrum UKE Hamburg, Klinik und Poliklinik f\u00fcr Kardiologie, Hamburg"},{"name":"Sana Hanse-Klinkum Wismar, Klinik f\u00fcr Innere Medizin und Kardiologie, Wismar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Steffel","sequence":"additional","affiliation":[{"name":"Swiss EP AG, Z\u00fcrich, und Universit\u00e4t Z\u00fcrich, Schweiz"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"G\u00f6tte","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II, Kardiologie, St. Vincenz-Krankenhaus GmbH, Paderborn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas W.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Kardiometabolik, Karl-Landsteiner-Gesellschaft, St. P\u00f6lten und Medizinische Fakult\u00e4t, Sigmund-Freud-Privatuniversit\u00e4t, Wien"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Waltenberger","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Med. I, SRH Zentralklinikum Suhl GmbH, Suhl"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"Universit\u00e4res Herz- und Gef\u00e4\u00dfzentrum UKE Hamburg, Klinik und Poliklinik f\u00fcr Kardiologie, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","author":"G Hindricks","year":"2020","journal-title":"Eur\u00a0Heart J"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12181-017-0141-5","article-title":"Kommentar zu den 2016 Leitlinien der Europ\u00e4ischen Gesellschaft f\u00fcr Kardiologie (ESC) zum Management von Vorhofflimmern","volume":"11","author":"L Eckardt","year":"2017","journal-title":"Der Kardiologe"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"C T Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"R P Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"M R Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/europace\/euy160","article-title":"Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS","volume":"21","author":"A J Camm","year":"2019","journal-title":"Europace"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jacc.2018.04.058","article-title":"Global Prospective Safety Analysis of Rivaroxaban","volume":"72","author":"P Kirchhof","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"ref10","first-page":"10","article-title":"Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program","author":"R de Caterina","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"f30","DOI":"10.1093\/ehjcvp\/pvaa079","article-title":"Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study","volume":"7","author":"J R de Groot","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12872-019-1144-x","article-title":"Characteristics of patients initiated on Edoxaban in Europe: baseline data from Edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)","volume":"19","author":"R de Caterina","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/STROKEAHA.117.018395","article-title":"Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"49","author":"M Proietti","year":"2018","journal-title":"Stroke"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2018.01.141","article-title":"The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation","volume":"258","author":"H Shimokawa","year":"2018","journal-title":"Int J Cardiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jjcc.2018.12.013","article-title":"Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance","volume":"73","author":"H Inoue","year":"2019","journal-title":"J Cardiol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1161\/CIRCULATIONAHA.115.015710","article-title":"Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study","volume":"132","author":"G Maura","year":"2015","journal-title":"Circulation"},{"key":"ref17","first-page":"7","article-title":"Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)","author":"B A Steinberg","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"ref18","first-page":"208","article-title":"Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study","volume":"75","author":"H Inoue","year":"2020","journal-title":"J\u00a0Cardiol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early Rhythm-Control Therapy in Patients with Atrial Fibrillation","volume":"383","author":"P Kirchhof","year":"2020","journal-title":"New England Journal of Medicine"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2328-7240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T15:55:58Z","timestamp":1730822158000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2328-7240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":19,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,7,16]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2328-7240","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"type":"print","value":"0012-0472"},{"type":"electronic","value":"1439-4413"}],"subject":[],"published":{"date-parts":[[2024,7,3]]}}}